205676-68-2

Upstream product

• 205676-67-1 3-[N-(tert-butoxycarbonyl)-N-methylamino]methyl-4-bromoanisole 
• 6163-58-2 tris-(o-tolyl)phosphine 
• 19614-12-1 2-bromo-5-methoxybenzyl bromide 
• 767289-08-7 N-(2-bromo-5-methoxybenzyl),N-methylamine 

Downstream Products

• 205676-69-3 methyl (+/-)-3-carbomethoxy-4-[2-(methylamino)methyl-4-methoxyphenyl]butanoate 

Relevant academic research and scientific papers

Treatment Method

The present invention is directed to methods of treating an ocular neovascular disorder in a mammal by administration of pyrimidine derivatives, benzodiazepinyl derivatives and pharmaceutical compositions containing the same. The invention encompasses methods of treating an ocular neovascular disorder by administration of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, (S)-3-oxo-8-[3-(pyridin-2-ylamino)-1-propyloxy]-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid or salts or solvates thereof. Combination therapies for the treatment of ocular neovascular disorders are also encompassed.

Vitronectin receptor antagonists

Compounds having a benzodiazepinyl core structure are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis, angiogenesis, tumor growth and metastasis, atherosclerosis, restenosis and inflammation.